We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.005 | -0.34% | 1.475 | 1.45 | 1.50 | 1.475 | 1.475 | 1.48 | 636,264 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.28 | 11.4M |
Date | Subject | Author | Discuss |
---|---|---|---|
02/2/2021 13:56 | Because (a) there may not be a placing; or (b) if there is to be one they expect the share price to rise before any fundraising is announced in late March / April; and (c) the share price should rise on a placing announcement because it's funding to enter a new market worth a multiple of the current market cap. | t0pgrader | |
02/2/2021 13:25 | Lovewins: could be that but one purchase alone could have achieved same effect imo. Also 10k purchases in market and then the rest in primary stock would also have same effect so I don’t think it’s that but thought provoking response all the same. Still I’m wrong often enough to be wrong again... | jackbal | |
02/2/2021 13:02 | Maybe in order to encourage the bigger holders to follow him at a 'cheaper' price to the one he took? Human nature, even if managing a fund involving customer money, to want to get what looks (and hopefully is!) a good deal. I bought more after his purchase and would not have done so at that point otherwise. One idea anyway. Must be due some news soon on such matters. | lovewinshatelosses | |
02/2/2021 12:19 | Agree Toffeeman as AGL already got theirs and a good Chunk too. Jupiter sold. job done. Thing that puzzles me here: why would directors make recent purchases on market if they knew they could get them cheaper in a near term placing? It would be like shorting yourself/throwing personal cash away.... Anyone have any views on this? | jackbal | |
02/2/2021 12:10 | Yes there is - STX will need to raise money at whatever price they can get AGL won't. | toffeeman | |
02/2/2021 11:51 | The cause of the short-term weakness is seemingly the persistence of the seller. An identical situation occurred recently in Angle where an ii believed to be Jupiter were selling at any price. Once done the share price rose from low 40s to 80p+ in the space of a few days. No reason to suppose the same won't happen here. | t0pgrader | |
02/2/2021 10:59 | Edison research is toilet paper. Quite how these companies expect paid for/bias research to boost sentiment/SP is beyond me. That said I liked the chunky director buys and continue to hold but now expecting more short term weakness as Edison do their “thing” whatever that is | jackbal | |
01/2/2021 15:04 | Wouldn’t cross the road to read a Edison update completely useless and on the pay check | best1467 | |
01/2/2021 11:40 | Edison values us at 298 million. Slight disparity | bobaxe1 | |
01/2/2021 11:38 | Wow current mcap at 64million | bobaxe1 | |
01/2/2021 10:09 | Here is the latest summary from Edison published this morning; Shield Therapeutics: Beefing up for the US opportunity Shield Therapeutics’ (STX’s) shares fell sharply in December 2020 on the announcement that a US partnering deal would not be completed in 2020 and that the company is considering launching Accrufer itself in the US. We believe the market reaction has been overdone and the current share price fully discounts any value from the US and China opportunities. Until STX provides further clarity, we have continued to evaluate it based on a US partnering deal. Our modelling suggests an STX-led US launch could more than double longer-term shareholder value, but this is accompanied by increased near-term financial and investment risk, as STX will need to raise funds to establish a small but focused US marketing organisation. We value STX at £298.5m. Register to download the whole thing from the Edison website. | innittowinit | |
30/1/2021 19:45 | Can anyone post up extracts of latest broker note for stx tia | senttothegallows | |
29/1/2021 17:44 | Grammar school calling | best1467 | |
29/1/2021 17:06 | Commenting on this update, Tim Watts, CEO of Shield Therapeutics plc, said: "I am very grateful to AOP and Dr Schweiger for making these loan facilities available to the Group as they will provide the cash runway and the time for the Board to reach the optimal outcome for shareholders regarding the commercialisation of Accrufer(R) in the US." Begging bowl out. ha ha Call him Oliver ha ha This guy is a idiot. They was running out of money by March 21 wow. Unbelievable. There know were nearer now to getting contract as they was before. Burn rate of money is bad as well. there not going get good deal as They will know they are struggling for money. Gone on far to long this. Hi should step down to be honest. | goforgold1 | |
28/1/2021 22:26 | This guy Tim . Is living in a dream. He has his head so much up,, His own Ass. Can not see the wood for the trees. By the time he gets to market he be collecting his pension. Lol .. He needs to go back to school To the do his business studies . As he has not got a clue .. | goforgold1 | |
28/1/2021 21:25 | Why is he even mentioning specific prices? If he'd just do his job properly the share price will take care if itself. | lako42 | |
28/1/2021 16:29 | Just listened to Tim on VOX and it was the most fluent I’ve heard him but I would just like to comment on one remark which I found Flabbergasting. He is clearly of the opinion the share fall as been overdone but he suggests that on a USA licensing deal the share price should get back to £1.20 range if not a little more is he not aware that 12 months ago we were trading at £1.70 in anticipation of a deal which you would of imagined would have driven the valuation above £2 it was just a crazy remark | best1467 | |
28/1/2021 13:13 | We all know TW isnt the world's best presenter but his performance on the podcast was fine. Definitely not "poor". | t0pgrader | |
28/1/2021 11:04 | I guess you prbably know this... generally anything he/they have done from an IR perspective will be found on hxxps://www.shieldth | innittowinit | |
28/1/2021 09:06 | do you have a link to the podcast please? | t0pgrader | |
28/1/2021 02:01 | Poor podcast with Mr waites. | letmepass | |
27/1/2021 22:54 | Told you all 45p | goforgold1 | |
27/1/2021 20:34 | Looking like lower lows on the chart. Sub 50p coming | letmepass | |
26/1/2021 21:25 | Massive move coming.....if not...all Technical Analysis principles which have not failed me for years are completely wrong for the very first time. Don’t get me wrong, the minor moves can be 70/30, but not the big longer timescale moves. All major methodologies are pointing to a Mkt Cap significantly North of where we are today. | hodhasharon | |
26/1/2021 21:18 | Second day running someone's building!// | bobaxe1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions